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E09: relationship between DT-diaphorase levels and response in vitro and
in vivo
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Summanr E09 [3-hydroxy-5-azinrdinyl-l-methyl-2( 1H-indole4.7-dione)-prop-fren-a-ol] was selected for
clinical tnral in Europe because of its preclinical profile but also because of its distinct mechanism of
bioactivation. Several studies have shown that cells rich in DT-diaphorase may be particularly sensitive to
E09- The present study examined the relationship between DT-diaphorase activity and sensitivity to E09 in a
panel of cell lines largely derived from human and rodent leukaemias lymphoma and solid tumours. A
possible relationship between chemosensitivity and enzyme activity was demonstrated (correlation coefficient
0.796). A number of the human cell lines were established as xenografts in nude mice but, with the exception
of HT29. DT-diaphorase specific activity was greatly reduced compared with the corresponding cell lines.
These data suggest that in vitro studies of bioactivation of drugs by specific enzymes is unlikely to be relevant
for the same tumour in vivo. Except for HCLO. all xenografts failed to respond to E09 as a single dose. HT29
tumours in vivo had similar DT-diaphorase activity [359 nmol of 2.6-dichlorophenol-indophenol (DCPIP)
reduced per min per mg of protein] to the cell line (337) but failed to respond to a single dose or daily dose
schedule. A preliminary attempt to investigate an hourly dose schedule demonstrated a modest anti-tumour
effect accompanied by enhanced toxicity. Attempts to optimise E09 exposure parameters to potentiate activity
in tumours with high DT-diaphorase activity are under way. but as yet the relevance of this particular enzyme
for in vivo E09 actiVity requires further investigation.
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E09 [3-hydroxy-5-aziridinyl- 1-methyl-2( 1H-indole-4,7-dione)-
prop-p-en-a-ol] is undergoing clinical evaluation in Europe
under the auspices of the EORTC New Drug Development
Coordinating Committee and EORTC New Drug Develop-
ment Office. It was selected for clinical study because of its
distinct mechanism of bioactivation. its activity against
hypoxic cells, its preferential solid tumour activity and its
lack of bone marrow toxicity in animal studies (Hendricks et
al., 1993). Bioreductive activation is thought to play a major
role in the mechanism of action of E09. The compound has
been shown to be a good substrate for reduction by human
and rodent DT-diaphorase [NAD(P)H: (quinone acceptor)
oxoreductase, EC 1.6. 99.2]. The two-electron reduction of
E09 via DT-diaphorase generates DNA-damaging species in
vitro (Walton et al.. 1991), and experiments performed with
DT-diaphorase-rich Walker tumour cells showed develop-
ment of DNA single-strand breaks and cross-links after
exposure to E09 (Bailey et al., 1992).
These studies suggest that cells nrch in DT-diaphorase may
be particularly sensitive to E09. Because of the small number
of studies describing relative expression of enzyme in tumour
vs normal tissue (Riley and Workman, 1992) and preliminary
observations demonstrating a correlation between E09 sen-
sitivity and DT-diaphorase expression in murine colon
tumours (Walton et al., 1992), there is a need for further
work in this area. A number of groups have now attempted
to correlate sensitivity to E09 with DT-diaphorase expres-
sion in panels of cell lines in vitro. Collard and Double (1992)
described three human cell lines with similar IC_% values for
E09 chemosensitivity but that had a 1500-fold difference in
enzyme activity. Robertson et al. (1992) examined a panel of
15 cell lines and concluded that the cell lines showing highest
levels of DT-diaphorase tended to be the most sensitive to
E09. This work has now been extended to cover 31 cell lines
and the conclusions still hold (Robertson et al., 1994). The
latest study used the enzyme inhibitor dicoumarol in an
attempt to confirm the role of DT-diaphorase in determining
drug sensitivity. A recent study by Smitskamp-Wilms et al.
(1994) showed, in a panel of seven human and four murine
tumour cell lines, that DT-diaphorase activity and gene ex-
pression predicted sensitivity to E09.
Preliminary studies in this laboratory have demonstrated
poor correlations between the activity of E09 in two human
tumour xenografts and their DT-diaphorase levels in vivo
(Collard et al., 1993). The present study examined initially
the relationship between levels of DT-diaphorase and sen-
sitivity to E09 in a panel of cell lines derived from rodent
and human leukaemias and solid tumours and hamster
fibroblasts. A number of the human lines were subsequently
established as xenografts in nude mice and tumour levels of
DT-diaphorase and sensitivity to E09 determined in vivo.
The aims of these studies were to investigate whether cell
lines reflected the solid tumour levels of DT-diaphorase and
also to determine whether it was possible to predict in vivo
sensitivity to E09 on the basis of enzyme level.
Materials and metbods
Chemicals
E09 was synthesised originally by Oostveen and Speckamp
(1987) and was supplied for this study by the EORTC New
Drug Development Office. For cell culture work E09 was
dissolved in RPMI-1640 medium and stored at -20°C until
required. For in vivo studies E09 was dissolved in stenrle
physiological saline immediately before use. The chemical
stability of the compound was checked by high-performance
liquid chromatography (HPLC) using a previously descnrbed
method (Phillips et al., 1992). DCPIP (2,6-dichlorophenol-
indophenol), dicoumarol(bis-hydroxycoumarin) and NADH
were purchased from Sigma, Poole, Dorset, UK.
Cell lines and culture conditions
A panel of cell lines (Table I) was grown in RPMI-1640
medium (Northumbria Biologicals, Cramlington. UK) supp-
lemented with 10% heat-inactivated fetal calf serum (Nor-
thumbria Biologicals), 1 mM sodium pyruvate (Life Tech-
nologies, Paisley, UK), 50 IU ml-' penicillin. 50 jg ml-'
streptomycin (Life Technologies) and 2mM L-glutamine
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Table I Cell line charactenrstics. DT-diaphorase activity and chemosensitivity to E09
(96 h exposure)
IC<O±s.d. IC+,±s.d. DT-daphorasea
Cell line Cell line characteristics (ngml- (nM} specific activity
MAC 13 Poorly differentiated 570 ± 14 1979 ± 49 -
murine adenocarcinoma
colon (Phillips et al.. 1990)
MAC 15A Murine ascitic tumour >1000 >3457 <1
derived from a solid
adenocarcinoma of the colon
(Phillips et al., 1990)
MAC 16 Slow-growing, cachectic 26 4 90 14 239 ± 10
murine adenocarcinoma of the
colon
(Phillips et al., 1990)
MAC 26 Well-differentiated murine 413 23 1434 ± 80 8.2 ± 1.3
adenocarcinoma of the colon
(Phillips et al., 1990)
WEHI-3B Murine myelomonocytic 308 ± 37 1069 ± 128 <1
leukaemia
(Warner et al., 1969)
K 562 Human chronic 18 ± 7 62 ± 24 1.9 ± 0.7
myelogenous leukaemia
(Lozzio and Lozzio, 1975)
RAJI TK- Burkitt's lymphoma 960 ±20 3332 ± 69 <1
DLD-1 Human colon 44 15 153 62 546 75
adenocarcinoma (Dexter
et al.. 1979)
HCT-18 Human adenocarcinoma of 27 ± 3 94 ± 10 303 ± 19
the colon
HCLO Human adenocarcinoma of 24 6 83 ± 21 319 ± 16
the colon
HRT-18 Human adenocarcinoma of 22 5 76± 17 247± 18
the rectum
HT-29 Human adenocarcinoma of 13 5 45 17 337 38
the colon
(Fogh and Trempe, 1975)
MCF-7 Pleural effusion of human 17 8 49 28 3014 138
breast carcinoma
(Soule et al., 1973)
MT-I Human breast carcinoma 13 2 45 7 579 11
(Hambly et al., 1994)
MT-3 Human breast carcinoma 16 2 56 7 556 ± 22
(Hambly et al., 1994)
MaTu Human breast carcinoma 24 4 83 ± 14 305b
(Hambly et al., 1994)
V-79 Chinese hamster lung 45 8 156 28 147 ± 1.9
aMeasured as nmol of DCPIP reduced min-' mg protein-'. bMean of two independent
determinations.
(Northumbria Biologicals). Cells were grown in 25 cm2 tissue
culture flasks (Costar UK, High Wycombe, UK) and
incubated at 37C in a humid atmosphere of 5% carbon
dioxide and 95% air. K562, RAJI TK- and WEHI-3B grew
in suspension, whereas the other cell lines formed
monolayers.
Chemosensitivity studies
Cells were harvested from stock cultures in exponential
growth and between 0.5 and 1 x IO' viable cells in 180pI of
RPMI-1640 were plated into 96-well culture plates. Follow-
ing a 4 h incubation at 37C, 20glI of drug solution at an
appropriate concentration was added to each well (eight wells
per drug exposure) to yield a range of final E09 concentra-
tions of 1 ng ml-' to 1 iLg mrl-'. Following a 4 day incubation
at 3TC in an atmosphere containing 5% carbon dioxide and
95% air, chemosensitivity was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Mosmann, 1983; Jabbar et al., 1989). Briefly, 150ILI of
old medium was removed and replaced with 150pl of fresh
medium immediately before the addition of 20 l of MTT
solution (5 mg ml-'). Following a 4 h incubation at 37C,
100 glI of medium plus MTlT was removed from each well
and the formazan crystals dissolved in 150jd of dimethylsul-
phoxide (DMSO). The absorbance of the resulting solution
was read at 550 nm using an enzyme-linked immunosorbent
assay (ELISA) spectrophotometer. All results were expressed
in terms of per cent survival taking the control absorbance
values to represent 100% survival. Cytotoxic effects were
expressed as IC50 values (concentration required to reduce
cell survival by 50%). All control cultures were in exponen-
tial growth at the time chemosensitivity was assessed.
Animals
NCR nude mice aged between 6 and 8 weeks were obtained
from the National Cancer Institute (NCI). They were housed
in isolation cabinets and received food (CRM, Labsure,
Croydon, UK) and water ad libitum. Animal experiments
were carried out under a project licence approved by the
Home Office, London, UK, and UK CCCR guidelines
(Workman et al., 1988) were followed throughout.
In vivo tumours
Human tumour xenografts were established in nude mice by
subcutaneous (s.c.) inoculation of cell lines derived from
established cell cultures. Solid tumour xenografts were pas-
saged from the established xenografts by the use of a trocar.
Tumours were grown subcutaneously in the flank or, in the
case of breast carcinomas, in the mammary fat pad and were
used for chemotherapy studies when consistent growth rates
were demonstrated - usually after five to six passages in vivo.The histological characteristics of each xenograft line have
been studied.
In vivo chemosensitivity studies
Chemotherapy commenced when tumours could be reliably
measured by calipers, i.e. when they had reached a minimum
diameter of 4-5 mm. Initial studies used a single intravenous
(i.v.) dose of E09 at a predetermined maximum tolerated
dose (Bibby et al., 1993, and further unpublished data from
this laboratory) of 6 mg kg-'. Further studies with the HT29
tumour employed a daily dose schedule (6 mg kg- ', single i.v.
bolus, each day for 4 days) or hourly dose schedule
(6mg kg-', i.v. bolus, each hour for 3 h). The effects of
treatment were assessed by sequential, two-dimensional
measurement of the tumours. Tumour volumes were cal-
culated using the formula a2 x b/2 and subsequently semilog
plots of relative tumour volume against time were produced.
Because of differences in volume doubling times of the
various tumours, anti-tumour effects were determined from
specific growth delay (Steel et al., 1983). Briefly, the end
point was taken at a relative volume of twice the size at the
start of treatment. The time for control and treated tumours
(T2,T2) to double their volume was determined and the
difference represents actual tumour growth delay. Specific
growth delay was calculated from the formula:
r2
T,
DT-diaphorase measurement
Cell lines were grown to approaching confluence in 75cm2
cell culture flasks in complete RPMI-1640 medium. Adherent
cell lines were harvested by trypsinisation with resulting
suspensions being washed in Hanks, buffered salt solution
(HBSS) before two further washes in ice-cold homogenisation
buffer [40 mM Tris-HCI buffer pH 7.6 containing 250mM
sucrose, 1 mM DL-dithiothreitol, 0.5 mM disodium EDTA,
0.3 mM phenylmethylsulphonyl fluoride (PMSF) and 10%
(v/v) glycerol. Suspension cultures were spun at 800g for
5 min and the pellet washed once with HBSS and twice with
ice-cold homogenisation buffer. All resulting cell suspensions
were kept on ice and sonicated with a Semat ultrasonic probe
and the cytosolic fraction obtained by ultracentrifugation at
104000g for I h at 4'C. The resulting supernatant was
divided into two, one being stored at - 20-C for subsequent
protein determination using the modified Lowry method
(Hartree, 1972) and the other immediately assayed for DT-
diaphorase. Tumours were excised and immediately placed in
ice-cold homogenisation buffer. Tumour weights were
recorded and samples were homogenised in four volumes of
homogenisation buffer in a Ultraturrax homogeniser. The
cytosolic fraction was prepared as above and, as for the cell
lines, samples were divided into two with one being stored
at - 20C for subsequent protein determination and the
second immediately assayed for DT-diaphorase. DT-
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diaphorase activity was measured as the dicoumarol-sensitive
reduction ofDCPIP (Siegel et al., 1990). Enzyme activity was
measured in cytosolic extracts at 25"C in 25 mM Ths buffer
pH 7.4 containing 200FM NADH and 40 FM DCPI. Bovine
serum albumin (BSA) was added at a final concentration of
0.2 mg ml-' to act as a DT-diaphorase activator. Enzyme
activity was calculated as the dicoumarol (20iM)-inhibitable
fraction using a molar extinction coefficient (e) for DCPIP
of 21 x 103 M- cm-'. The activity of DT-diaphorase in the
samples was then related to protein content. All assays were
carried out in triplicate and a minimum of four separate
samples were assayed for each tumour line.
Resuis
Cell line characteristics, DT-diaphorase specific activity and
chemosensitivity to E09 following a % h exposure are pres-
ented in Table I. IC50 values ranged from 45 nM for the
human carcinoma cell lines HT-29 and MCF-7 up to >3 FLM
for the human Burkitt's lymphoma cell line, RAJI TK- and
the murine colon adenocarcinoma cell line MAC15A. DT-
diaphorase specific activity ranged from <1 nmol of DCPIP
reduced per min per mg of protein in MAC15A, WEHI-3B
and RAJI TK- up to 3014 nmol DCPIP reduced per min per
mg of protein in MCF-7. The relationship between chemo-
sensitivity and enzyme activity is demonstrated in Figure 1.
There is a reasonable correlation between both parameters
(correlation coefficient 0.7%), with the most sensitive cell
lines showing highest DT-diaphorase activity. The human
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Figwe 1 A comparison of E09 sensitivity (96 h exposure in air)
and DT-diaphorase activity in the panel of cell lines.
Table H DT-diaphorase activity ofhuman tumourxenogafts and sensitivity to E09. Growth
delay isthedifferenceintimetakenforcontrol andtreated tumourstodouble involume. Specific
growth delay is this value divided by the specific tumour volume doubling time.
DT-daphorase- Tumour vohme Anti-tumour activity (days)
specific activity doubling time Spec#fc growth
Tunour (mean ± s.d.) (days) Growth delay delay
DLD-1 27 4.0 9 0 0
HCT-18 68.1 5.8 5 0 0
HCLO 11.6 1.7 4 10 2.5
HRT-18 35.5 8.0 8 4 0.5
HT-29 359±45 10 0 0
MT-1 39.9±5.7 4 0 0
MT-3 57.9 22.9 7 1.5 0.21
MaTu 32.7 22.5 14 0 0
MVBO 1.47 0.26 10 3 0.3
'Measured as nmol of DCPIP reduced min' mg protein-'.
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leukaemia K562 is exceptional in that it is highly sensitive to
E09 but has low DT-diaphorase activity. Exclusion from the
correlation of the only hamster cell line used (V79) did not
markedly alter the correlation coefficient (r2 = 0.807).
Results of in vivo investigations are presented in Table II.
For the human tumour xenografts successfully established in
vivo tumour volume doubling times ranged from 4 to 14
days. With the exception of HT29. each of the solid tumours
demonstrated greatly reduced DT-diaphorase specific activity
compared with the cell lines, and almost all failed to respond
significantly to E09. One breast cancer cell line which was
established as a xenograft (MVBO) had particularly low
enzyme activity but unfortunately failed to grow in long-term
cell culture. It did not respond significantly to E09 in vivo.
HT29 possessed similar enzyme activity when grown as a cell
line or as a solid tumour in nude mice. but even though the
cell line was quite sensitive to E09 the solid tumour failed to
respond. Further studies using a daily dose schedule
(6 mg kg-'. i.v.) failed to produce measurable anti-tumour
effects even though there was considerable body weight loss
(>10%) and 1 9 deaths in the treated group. A preliminary
study designed to evaluate the potential of hourly scheduling
against HT29 examined 6 mg kg'. i.v.. hourly for 3 h. This
treatment resulted in 30% mean tumour inhibition on day 7
(calculated from tumour volumes from control and treated
mice) but only 2 10 mice survived until day 14 after treat-
ment. The only tumour xenograft of the series to show
measurable growth delay following single-dose E09 treat-
ment was HCLO (Table II). Effects against this tumour were
quite good. with the 10 day growth delay representing 2.5
times the volume doubling time of the tumour. DT-
diaphorase activity in the HCLO tumour, however, was
shown to be low.
Discussion
This study set out to examine the relationship between levels
of DT-diaphorase and sensitivity to E09 in vitro and in vivo.
Correlation between DT-diaphorase activity and IC50 values
in vitro was reasonable, confirming the observations of
Robertson et al. (1994) and Smitskamp-Wilms et al. (1994).
All three of these studies provide evidence to suggest that cell
lines possessing high levels of DT-diaphorase may be good
targets for E09 treatment. although. clearly, there must be a
number of other factors that can influence the cell line res-
ponses.
In the present investigation we have extended the in vitro
work into animal studies, concentrating on the human cell
lines that grow as human tumour xenografts in nude mice.
The range of enzyme levels measured in solid tumours was
disappointing with one tumour line only (HT29) demon-
strating a similar level as a solid tumour to that seen in the in
vitro cell line. The other tumours all had much lower levels of
enzyme. so the panel of xenografts could therefore not be
used to correlate directly DT-diaphorase activity with res-
ponse to E09. as had been the original aim of the study. Of
course, solid tumours will have many different cell types and
also contain cell debris. all of which might lead to an
underestimate of the actual DT-diaphorase content of the
tumour cells themselves. On the other hand, it may be that
levels of DT-diaphorase in the cell lines are artificially high
owing to different microenvironmental factors including pos-
sible oxidative stress.
Because of the extremely short plasma half-life of EO9 in
mice (Workman et al.. 1992: Bibby et at.. 1993). it is likely
that high tumour levels of enzyme would be necessary to
reduce sufficient drug to produce measurable anti-tumour
effects. This being the case. the clear response seen against
the HCLO tumour needs further evaluation as this tumour
was shown to possess low DT-diaphorase activity. The two-
electron reduction of E09 by DT-diaphorase results in prod-
uction of the hydroquinone. but one-electron reduction by
enzymes such as cytochrome P450 reductase can also occur,
giving rise to the semiquinone. Bailey et al. (1993) have
demonstrated the reduction of E09 by purified cytochrome
P450. It is thought that in cells high in DT-diaphorase E09
is preferentially metabolised by this enzyme in air or hypoxic
conditions, whereas in cells low in DT-diaphorase enzymes
such as P450 reductase are more important in this respect.
Robertson et al. (1994) have demonstrated that in cells high
in DT-diaphorase treatment with E09 in hypoxia does not
influence toxicity, whereas in cells with low DT-diaphorase
activity in hypoxia is greatly increased. The authors interpret
these observations as evidence that both one- and two-
electron reductive processes are operating and that in cells
low in DT-diaphorase activity one-electron reduction is
important for toxicity in hypoxia as oxygen is not present to
reverse the process. It is possible then that other enzymes are
important for the cytotoxicity of E09 against HCLO.
The lack of in vivo activity against HT29 tumours follow-
ing single and daily dose schedules of E09 was disappoin-
ting, since this tumour was shown to possess similar enzyme
activity to the cell line. The most likely explanations for this
lack of activity are that effective drug exposure parameters
are not being achieved in the tumour or that levels of reduc-
ing enzymes within the tumour are not high enough to
activate sufficient quantities of the drug. Although the in
vitro studies here utilised 96 h exposures. the half-life of E09
in RPMI 1640 is only 6.3 h (Phillips et al.. 1992). Even
taking this into account, the duration of exposure may still
be too long to mimic that achievable in vivo. The importance
of exposure time for anti-tumour effects might best be dem-
onstrated in vitro by the use of much shorter drug exposure
times than those employed here. The preliminary hourly
dosing schedule suggests that it may be possible to obtain
responses by optimising drug doses and schedules, but
whether this can be achieved in the absence of normal tissue
toxicity needs to be established. Hendriks et al. (1993)
showed that the activity of E09 against the MRI-H-207
human ovarian xenograft was similar when single in-
traperitoneal administration on day 0 and day 7 was com-
pared with an every hour x 6 schedule; but the hourly
schedule appeared less toxic. Studies by Adams et al. (1992)
demonstrated that E09 was inactive against the KHT sar-
coma in mice but the compound could potentiate the action
of 10 Gy X-irradiation. This dose of radiation is sufficient to
eradicate the aerobic fraction, implying that E09 can work
as a hypoxic toxin in vivo and may well be effective in
combination with other modalities.
In conclusion, this study has demonstrated a relationship
between DT-diaphorase activity and chemosensitivity to E09
in a panel of rodent and human cell lines. In general, the cell
lines which possess high levels of DT-diaphorase tend to be
the most responsive to E09. With the exception of HT29,
human tumour xenografts in nude mice. developed from a
number of these cell lines, had much less DT-diaphorase
activity than the corresponding cell line. Only HCLO res-
ponded to single-dose E09, and this tumour was low in
DT-diaphorase activity. Attempts to optimise drug exposure
parameters in tumours with high enzyme activity are cur-
rently ongoing.
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